This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Hoffmann-La Roche
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT02171429
First received: June 20, 2014
Last updated: March 9, 2017
Last verified: March 2017
  Purpose
This phase III, double blind, placebo and active comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active UC who are naïve to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Condition Intervention Phase
Ulcerative Colitis Drug: Adalimumab Other: Adalimumab Placebo Drug: Etrolizumab Other: Etrolizumab Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of participants with induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) [ Time Frame: Week 10 ]

Secondary Outcome Measures:
  • Percentage of participants with induction of remission compared with adalimumab as determined by the MCS [ Time Frame: Week 10 ]
  • Percentage of Participants With Anti-therapeutic Antibodies (ATA) [ Time Frame: Pre-dose (0 hour) on Day 1, Week 4, Week 10 and Week 14 ]
  • Percentage of participants with induction of clinical remission as determined by the MCS [ Time Frame: Week 10 ]
  • Percentage of participants with clinical response as determined by the MCS [ Time Frame: Week 10 ]
  • Percentage of participants with improvement in endoscopic appearance of the mucosa as determined by the Mayo Endoscopic Subscore [ Time Frame: Week 10 ]
  • Percentage of participants with endoscopic remission as determined by the Mayo Endoscopic Subscore [ Time Frame: Week 10 ]
  • Percentage of Participants who Achieve Remission at Week 10 and who Maintained Remission to Week 14 as Determined by MCS [ Time Frame: Week 10 and 14 ]
  • Percentage of participants with histological remission as determined by the Geboes Histological Subscore [ Time Frame: Week 10 ]
  • Percentage of participants with remission, among alpha E integrin high participants as determined by the MCS [ Time Frame: Week 10 ]
  • Change from baseline to Week 10 in UC bowel movement signs and symptoms, as assessed by UC-Participant-Reported Outcome Signs and Symptoms (PRO/SS) [ Time Frame: Baseline, Week 10 ]
  • Change from baseline to Week 10 in UC abdominal symptoms, as assessed by UC-PRO/SS [ Time Frame: Baseline, Week 10 ]
  • Change from baseline to Week 10 in health-related Quality of Life (QOL), as assessed by overall Inflammatory Bowel Disease Questionnaire (IBDQ) [ Time Frame: Baseline, Week 10 ]
  • Pharmacokinetics of Etrolizumab: Serum Concentration [ Time Frame: Pre-dose (0 hour) on Day 1, Week 10 and Week 14 ]

Estimated Enrollment: 350
Actual Study Start Date: November 30, 2014
Estimated Study Completion Date: March 31, 2018
Estimated Primary Completion Date: March 31, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Adalimumab + Etrolizumab Placebo
Participants will receive adalimumab up to Week 8 and placebo matched to etrolizumab up to Week 14.
Drug: Adalimumab
Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
Other: Etrolizumab Placebo
Placebo matched to etrolizumab will be administered SC Q4W.
Experimental: Etrolizumab + Adalimumab Placebo
Participants will receive etrolizumab up to Week 14 and placebo matched to adalimumab up to Week 8.
Other: Adalimumab Placebo
Placebo matched to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.
Drug: Etrolizumab
Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).
Placebo Comparator: Etrolizumab Placebo + Adalimumab Placebo
Participants will receive placebo matched to etrolizumab up to Week 14 and placebo matched to adalimumab up to Week 8.
Other: Adalimumab Placebo
Placebo matched to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.
Other: Etrolizumab Placebo
Placebo matched to etrolizumab will be administered SC Q4W.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of UC established at least 6 months prior to randomization
  • Moderately to severely active UC as determined by the MCS
  • Naive to treatment with any anti-TNF therapy
  • An inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment
  • Background UC therapy may include oral 5-aminosalisylate (ASA), oral corticosteroids, budesonide multi-matrix system (MMX), probiotics, azathioprine (AZA), 6-mercaptopurine (MP), or methotrexate (MTX) if doses have been stable for the 8 weeks immediately prior to randomization
  • Use of highly effective contraception method as defined by the protocol
  • Have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening

Exclusion Criteria:

  • A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, stricture (stenosis) of the colon, toxic megacolon, or unremoved adenomatous colonic polyps
  • Prior or planned surgery for UC
  • Past or present ileostomy or colostomy
  • Have received non-permitted inflammatory bowel disease (IBD) anti-integrin therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol
  • Congenital or acquired immune deficiency, chronic hepatitis B or C infection, HIV positive
  • Evidence of or treatment for Clostridium difficile within 60 days prior to randomization or other intestinal pathogens within 30 days prior to randomization
  • History of active or latent tuberculosis (TB), recurrent opportunistic infections, severe disseminated viral infections and organ transplant
  • Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening
  • Received a live attenuated vaccine within 4 weeks prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02171429

Contacts
Contact: Reference Study ID Number: GA28949 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.rochegenentechtrials@roche.com

  Show 144 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02171429     History of Changes
Other Study ID Numbers: GA28949
2013-004277-27 ( EudraCT Number )
Study First Received: June 20, 2014
Last Updated: March 9, 2017

Additional relevant MeSH terms:
Colitis
Ulcer
Colitis, Ulcerative
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on June 26, 2017